Abstract 1961P
Background
Sarcomas are rare malignant tumors and represent a heterogeneous group of tumors. An accurate diagnosis of histology is important for treatment strategies. We assessed the pathological review of all patients diagnosed with sarcoma at Siriraj Hospital over a 5-year period to identify the number of first diagnoses compared to the central expert review.
Methods
Histological data from patients diagnosed with sarcoma at Siriraj Hospital were collected over a 5-year period. The initial diagnoses were compared with a certified soft tissue and bone tumor pathologist.
Results
Of the 185 selected patients, 107 (57%) met the inclusion criteria and were analyzed. Full concordance between primary diagnosis and second opinion (the first pathologist and expert reached identical conclusions) was observed in 35 (32.7%) cases, partial concordance (identical diagnosis of connective tumor but different grade or histological type) in 12 (11.2%) cases, and complete discordance (benign versus malignant, different histological type, or invalidation of the diagnosis of sarcoma) in 60 (56.1%) cases. The rate of discordance was higher in incomplete initial IHC (p = 0.003), private laboratory, grade 2 and 3, tumor size ≥ 100 mm (p = 0.01) and age >18. The most common 'full concordance' histology is osteosarcoma (100%, 4 of 4). The main discrepancies were related to histological type (n = 60, 56.1%), subtype (n = 8, 7.5%), and grade plus subtype (n = 4, 3.7%). The mean duration from diagnosis to treatment was 96 days. Only the complete initial report appeared different in the subgroup <97 days group 39 (73.6%) and 97 days group 14 (26.4%) (p=0.03).
Conclusions
More than 65% of the first histological diagnoses were modified in the second reading, possibly resulting in different treatment decisions. The second opinion of the expert improves the quality of diagnosis and possibly the treatment of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1929P - phase II results from the RINGSIDE phase II/III trial of AL102 for treatment of desmoid tumors
Presenter: Bernd Kasper
Session: Poster session 15
1930P - phase II trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (KCSG UN18-06)
Presenter: Young Saing Kim
Session: Poster session 15
1931P - Ultra-rare sarcomas have worse survival compared to non-ultra-rare sarcomas: A national cancer registry study
Presenter: MIng-Jing Lee
Session: Poster session 15
1932P - First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma
Presenter: Jose Antonio González
Session: Poster session 15
1933P - Perioperative chemotherapy could reduce the risk of recurrence in resected leiomyosarcoma of the vena cava (LMS-VC): A retrospective bi-centric series on 41 patients
Presenter: Thibaud Bertrand
Session: Poster session 15
1934P - Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma
Presenter: Brian Van Tine
Session: Poster session 15
1935P - Exploration of tertiary lymphatic structure in soft tissue sarcoma for the prognostic and immunotherapy response
Presenter: Wang Xiang-Xu
Session: Poster session 15
1936P - Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling
Presenter: Marcus Renner
Session: Poster session 15
1937P - KM-subtraction meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma
Presenter: Qin Jian Low
Session: Poster session 15
1938P - Assessment of clinical benefit of cancer drugs recommended in National Comprehensive Cancer Network (NCCN) guidelines for advanced soft tissue sarcomas (STS) and bone sarcomas (BS)
Presenter: Maria Aguado Sorolla
Session: Poster session 15